Search Results
Patients
We believe that each of us deserves a chance for a full life, free from illness and full of possibilities.
Corporate Responsibility Report
We’re motivated every day to positively impact the lives of others. Driven by our mission to save and sustain lives, we strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.
Sustainability
Sustainability is central to Baxter’s vision of building a truly great company by providing enduring value for all stakeholders.
New report highlights the vital role of TGA-licensed compounders and the urgent need to address funding shortfall
A report by Shawview Consulting for the TGA-Licensed Chemotherapy Compounders of Australia (TLCCA), representing Baxter Healthcare, Slade Health, and Wesley Pharmacy clearly demonstrates their value to cancer patients and health care more broadly, and the urgent need for the Federal Government to provide the funding needed to ensure timely and equitable access to compounded cancer medicines for all Australians.
Baxter Healthcare and Australian Government announce $40 million investment towards strengthening sovereign supply of IV fluids
Baxter Healthcare (Baxter), an innovative leader in infusion therapies and technologies and Australia’s only onshore manufacturer of IV fluids, and the Australian Government today announced a landmark $40 million investment toward the company’s expansion of its Australian IV fluids manufacturing facility in Old Toongabbie, Western Sydney.
13 August, 2024 - Supply Status of Sterile Fluid Products in Australia
Patient care is our top priority. Currently, there is significantly heightened demand for intravenous (IV) and irrigation fluids across Australia due in part to supply limitations and manufacturing issues from other suppliers1.